In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory cytokines to promote tumor progression. In particular, the inflammatory cytokine, interleukin-1 (IL-1), is elevated in prostate cancer (PCa) patient tissue and serum, and promotes PCa bone metastasis.
| INTRODUCTION
Inflammatory cytokines are present in the tumor microenvironment due to infiltrating immune cell paracrine secretion and tumor cell autocrine signaling. 1 The normal function of inflammatory cytokines includes signaling the destruction and removal of damaged and foreign cells in wound healing. 1 Tumor cells, however, have evolved mechanisms that use inflammatory cytokines to promote tumor cell survival and disease progression. 1 For example, in prostate cancer (PCa), the interleukin-1 (IL-1) inflammatory cytokine family member, IL-1 beta (IL-1β), has been shown to promote PCa tumor angiogenesis 2 and PCa metastasis and bone colonization, 3 thereby contributing to PCa progression.
We and others have shown that IL-1β and the other major IL-1 family member, IL-1 alpha (IL-1α), can repress androgen receptor (AR) accumulation and activity. [4] [5] [6] [7] AR is a nuclear receptor transcription factor. 8 AR and its hormone ligand, androgen, are required for prostate cell growth. 8 As such, AR drives PCa initiation and progression and is a PCa therapeutic target. 8 Therapies that target and block AR signaling include chemical or surgical androgen deprivation (hormone therapy) or treatment with anti-androgen antagonists which directly bind AR. 8 AR-targeted therapies are initially effective, but PCa patients can relapse within a few years and develop bone metastatic tumors that acquire androgen independence and treatment resistance. 9 Treatment at the bone metastatic stage is palliative, 9 highlighting the need to investigate and rigorously dissect mechanisms of PCa progression and acquired resistance to AR-targeted therapy.
The intended target of androgen deprivation and anti-androgens are the AR + luminal cells which comprise the bulk of the prostate adenocarcinoma tumor. 10 However, the AR + luminal PCa cells can evolve androgen independence and AR-targeting drug resistance due to multiple different mechanisms, including AR overexpression, AR gene mutation, or androgen-independent AR activation. 10 Another mechanism of androgen independence and treatment resistance is the accumulation of the AR − prostate gland cell types-basal, neuroendocrine, or stem cells-which are not susceptible to AR-targeting therapy and thus can repopulate the tumor and contribute to relapse. 10 Importantly, it has been found that high grade, metastatic, and castration-resistant PCa tumors are enriched in cells with low or no accumulation of AR 11, 12 or the AR target gene, Prostate Specific Antigen (PSA), 13 suggesting that the loss of AR activity is associated with PCa progression. It is thus becoming increasingly apparent that PCa tumors with low or no AR accumulation or activity, either through the enrichment of AR − prostate gland cell types or the de novo reduction or loss of AR in AR + luminal cells, represent an inherently treatment resistant cell phenotype that should not be overlooked and warrants further study.
We propose that a possible mechanism of AR-targeted treatment resistance and PCa tumor progression is IL-1-mediated AR repression in luminal PCa cells. Clinical support for such a mechanism is the observation that PCa patient bone metastases show an inverse correlation between IL-1β and AR protein accumulation in tumor cells. 3, 14 Bone-derived immune cells present in the tumor microenvironment can also produce high levels of IL-1 1 ;
and we previously discovered that the secretory bone marrow stromal cell (BMSC) line, HS-5, which secretes IL-1α and IL-1β, 15 causes paracrine repression of AR mRNA and protein in PCa cell lines. 4 Concomitant with AR repression, we found that HS-5 bone marrow stromal cells (BMSCs) also induce prosurvival proteins, one of which, Sequestome-1 (p62), is also induced by IL-1β. 4, 16, 17 p62 is an adaptor protein that functions in inflammatory, antioxidant, and autophagy pathways 18 and is cytoprotective for AR − PCa cell lines. 16 Therefore, we hypothesize that IL-1 promotes PCa progression and treatment resistance by reprograming AR + PCa cells into AR − PCa cells that acquire AR-independent survival and tumor promoting mechanisms. To begin to address our hypothesis, we set out to identify the IL-1-confered gene expression profile in AR + PCa cells that mimics AR − PCa cell gene expression patterns to uncover the elicited signaling pathways that might promote AR-independent PCa cell survival and tumorigenesis.
| MATERIALS AND METHODS

| Cell culture
LNCaP, MDA-PCa-2b, PC3, and DU145 PCa cell lines, and HS-5 and HS-27a bone marrow stromal (BMSC) cell lines were grown in a 37°C, 5.0% (v/ v) CO 2 growth chamber. All cell lines, except for MDA-PCa-2b, were cultured in Gibco DMEM (#11885092, Thermo Fisher Scientific, Grand Island, NY) supplemented with 10% (v/v) fetal bovine serum (FBS) alternative, Seradigm FB Essence (#3100-500, VWR, Radnor, PA), 0.4 mM Gibco L-glutamine (L-glut; #25030-081, Thermo Fisher Scientific), and 10 U/mL Gibco penicillin G sodium and 10 mg/mL streptomycin sulfate (pen-strep; #15140-122, Thermo Fisher Scientific). MDA-PCa-2b cells were cultured in BRFF-HPC1, (#0403, AthenaES, Baltimore, MD) supplemented with 20% (v/v) FB essence, 0.4 mM L-glut, and 10 U/mL Gibco penicillin G sodium and 10 mg/mL streptomycin sulfate (pen-strep; #15140-122, Thermo Fisher Scientific). Interleukin-1 Receptor Antagonist (IL-1Ra): Cells were pre-treated for 1 or 2 days with PBS vehicle control or 500 ng/mL human recombinant IL-1Ra (#280-RA/CF, R&D Systems) in the DMEM/10% FB essence growth medium. The next day the medium was removed and replaced with fresh DMEM/10% FB essence (control CM) or HS-5 CM, plus an additional 500 ng/mL IL-1Ra for 1 or 3 days. PBS served as the IL-Ra vehicle control.
| Cell treatments
| Conditioned medium (CM)
| RNA isolation and reverse transcription quantitative PCR (RT-QPCR)
Total RNA was extracted from the cells using the GeneJET RNA Purification Kit according to the manufacturer's instructions (# K0732, Thermo Fisher Scientific). cDNA was generated using iScript Reverse Transcription Supermix (#1708841, Biorad, Hercules, CA). The RT-QPCR reaction was prepared using iTaq Universal SYBR Green Supermix (#1725125, Biorad). Primer sequences for genes of interest are listed below. Gene of interest cycle times (CT) were normalized to the β-actin.
Relative mRNA levels were calculated using the 2 −ΔΔCT method. 
| RNA-sequencing analysis
Fastq files were checked for quality using fastqc (v0.11.2) 19 and fastq_screen (v0.4.4), 20 and were quality trimmed using fastq-mcf (eautils/1.1.2-806). 21 Trimmed fastq files were mapped to mm10 (UCSC version from igenomes) using TopHat, 22 duplicates were marked using picard-tools (v1.127 https://broadinstitute.github.io/picard/), read counts were generated using featureCounts 23 and differential expression analysis was performed using edgeR. 24 Pathway analysis was conducted using QIAGEN's Ingenuity Pathway Analysis tool (http://www.qiagen.com/ingenuity, Qiagen, Redwood City, CA). RNAseq datasets generated for this study are available at GEO NCBI, accession GSE105088. 
| Western blot
| Statistical analysis
Statistical significance was determined using unpaired student t-test.
Graphs are shown as the average of a minimum of n = 3 biological replicates +/− standard deviation (STDEV).
| RESULTS
| IL-1β modulates a suite of genes in LNCaP PCa cells that mimics basal PC3 PCa gene expression patterns
Based on our previous observations that HS-5 BMSC CM or IL-1β
repress AR mRNA levels in AR + PCa cell lines concomitant with induced expression of prosurvival p62, a gene constitutively expressed in AR − PCa cell lines, 4, 16 we set out to identify the gene expression profile acquired by IL-1-exposed AR + PCa cells that mimics intrinsic gene expression in AR − PCa cells. In doing so, we would identify conserved mechanisms that promote PCa cell survival and tumor progression either as a consequence of or despite AR loss or reduction. To obtain a profile of genes that might drive AR + PCa cells toward an AR − PCa cell molecular phenotype, we performed Figure 1A and Supplementary Table S1 ).
To identify a gene expression pattern representing IL-1βdependent HS-5 paracrine signaling in LNCaP cells, we first obtained a consensus list of 1644 genes that were either induced or repressed at least twofold in both gene sets (1) and (2) (log fold change (logFC) ≥1 or ≤−1, false discovery rate (FDR) ≤0.05, and log counts per million (logCPM)>0) ( Figure 1A and Supplementary Table S1 ). Next, to identify genes that are induced or repressed by IL-1β in LNCaP cells and are, respectively, basally high or low at least 1.5-fold in PC3 cells, we took the union of the intersection between the 1644 genes list and gene set (3) and the 1644 genes list and gene set (4) (logFC ≥0.6 or ≤ −0.6, FDR ≤ 0.05, logCPM>0) ( Figure 1A and Supplementary Table S1 ). The union produced a list of 1046 genes ( Figure 1A and Supplementary   Table S1 ), which represent an IL-1β-induced gene expression profile in LNCaP cells that mimics basal PC3 gene expression patterns ( Figures 1A and 1B ).
We previously published that IL-1β represses AR mRNA expression in AR + PCa cell lines, yet cells can remain viable. 4 Therefore, the 1046 gene expression profile we generated might provide insight into genes and pathways that confer AR-independent PCa cell survival and treatment resistance.
| HS-5 CM, IL-1α, and IL-1β show similar regulation of selected genes from our expression profile in AR + PCa cell lines
The 1046 genes list is based on a comparison between HS-5 CM and IL-1β treatments in LNCaP cells. To confirm the RNA-seq data and to determine if IL-1α induces similar gene regulation in LNCaP cells, we performed quantitative RT-PCR (RT-QPCR) and/or Western blot analysis for rationally selected genes based on previous studies showing IL-1 regulation 4 (p62, AR, and AR target genes 25 , PSA, NKX3.1, and TMPRSS2) or randomly selected genes (CD24, CD44, ELF3, and SOX9) from the 1046 genes list ( Supplementary Table S1 ). RT-QPCR and/or Western blot confirmed that AR, PSA, NKX3.1, and TMPRSS2 are repressed by HS-5 CM ( Figures 2B and 2D ), IL-1α ( Figures 3A and 3C ), or IL-1β ( Figures 3A and 3C) in LNCaP cells and are basally low or absent in PC3 cells (Figure 2A) . Likewise, RT-QPCR and/or Western blot confirmed that p62, ELF3, SOX9, CD24, and/or CD44 are induced by HS-5 CM ( Figures 2C and 2D ), IL-1α ( Figures 3B and 3C ), or IL-1β ( Figures 3B and 3C) in LNCaP cells and are basally high in PC3 
| PC3 cells show IL-1-independent expression levels of selected genes from the 1046 genes list
The 1046 genes list is comprised of IL-1-induced or-repressed genes in LNCaP cells that are basally high or low, respectively, in PC3 cells.
However, this does not preclude IL-1 from modulating expression of these genes in PC3 cells. Interestingly, while HS-5 CM (Figure 2 
| IL-1 signaling is sufficient to mediate HS-5 BMSC paracrine modulation in AR + PCa cell lines of selected genes from the 1046 genes list
HS-5 CM contains a milieu of cytokines 15 ; therefore, we reasoned that the intersection between the HS-5 CM-modulated gene set and IL-1βmodulated gene set in LNCaP cells ( Figure 1A and Supplementary   Table S1 ) are those genes regulated by HS-5 BMSCs through IL-1 paracrine signaling. To provide support for our reasoning, we incubated LNCaP cells with IL-1Ra in the presence of HS-5 CM and used RT-QPCR to determine if IL-1Ra could attenuate HS-5 CM regulation of selected genes. As an indication of IL-1Ra treatment efficacy, we found that IL-1Ra is sufficient to attenuate HS-5 CM-induced SOD2 mRNA ( Figure 5B ) in LNCaP cells. IL-1Ra also attenuates HS-5 CM-induction of p62, ELF3, SOX9, CD24, and CD44 mRNA ( Figure 5B ) and attenuates HS-5 CM repression of AR, PSA, and NKx3.1 mRNA ( Figure 5A ), but not TMPRSS2 mRNA levels. MDA-PCA-2b cells show similar responses to IL-1Ra as LNCaP cells (Supplementary Figure S3 ). Thus, the gene expression patterns induced by IL-1mediated BMSC paracrine signaling in AR + PCa cell lines is likely conserved in PCa. NKX3.1, TMPRSS2, p62, ELF3, SOX9, CD24 , and CD44 Levels. PC3 cells were pretreated with 500 ng/mL Interleukin-1 Receptor Antagonist (IL-1Ra) for 1 day (to analyze basally high genes) or 2 days (to analyze basally low genes). Following pretreatment, the growth medium was replaced with PC3 conditioned medium (Control CM) + 500 ng/mL IL-1Ra or with HS-5 CM + 500 ng/mL IL-1Ra for an additional 1 day (to analyze basally low genes) or 3 days (to analyze basally high genes). PBS is the IL-1Ra vehicle control. RT-QPCR was performed for PC3 cells. IL-1Ra attenuates HS-5 CM-induced SOD2 mRNA, indicating IL-1Ra treatment efficacy. IL-1Ra does not modulate basal AR, PSA, NKX3.1, TMPRSS2, p62, ELF3, SOX9, CD24 
| The 1046 genes list expression profile is predicted to regulate inflammatory, immune, and AR signaling pathways
| IL-1 signaling may promote the de novo accumulation of AR low/− PCa cells
In addition to tumor autocrine signaling, infiltrating bone-derived immune cells and tumor stromal cells secrete inflammatory cytokines and these cytokines have various pro-and anti-tumorigenic functions. 33 Thus, dissecting the paracrine interactions in the inflammatory tumor microenvironment better defines tumor biology and reveals cell survival mechanisms that could be therapeutically targeted.
Inflammation is implicated in PCa initiation, progression, and treatment resistance, 34 as such, PCa cells are not only exposed to a rich inflammatory cytokine environment in the primary tumor, but in the bone microenvironment, as well, where PCa cells preferentially metastasize. Thus, to explore how bone cell paracrine signaling effects PCa cell survival, we had previously shown that the macrophage-like, secretory BMSC line, HS-5, secrete factors that induce apoptosis in multiple different AR + PCa cell lines 35 ; however a subpopulation of the HS-5 CM-treated cells survive apoptosis, elicit cytoprotective autophagy and transdifferentiate into neuroendocrine-like cells that lose AR and have elevated p62 accumulation. 4, 16, 17, 35 We found that HS-5-secreted interleukin-6 (IL-6) promotes PCa autophagy and neuroendocrine differentiation, 17 and that HS-5-secreted IL-1 mediates AR loss and p62 accumulation 4 (Figures 5 and S3 ). Interestingly, AR − PCa cell lines show reduced sensitivity to HS-5-induced apoptosis and have high basal autophagy, neuroendocrine makers, and cytoprotective p62 accumulation. 16, 17, 35, 36 Therefore, a pattern emerges wherein HS-5 BMSCs cause AR + PCa cells to acquire an AR − PCa prosurvival phenotype. and re-emerge in treatment resistant tumors. Thus, IL-1-targeted therapies, such as the FDA approved anti-inflammatory IL-1Ra drug, anakinra, 37 could be used to prevent the de novo accumulation of AR low/− PCa cells. Chronic exposure to IL-1, however, is likely to produce AR low/− PCa cell subpopulations that develop the ability to maintain constitutive activation of IL-1-confered pathways independent of IL-1 receptor activity, similar to what we observe for PC3 cells (Figure 4) . Thus, targeting such downstream pathways would predictably be effective against both IL-1-sensitive AR + PCa cells and AR low/− PCa cells that have evolved IL-1-independence.
| The IL-1-confered 1046 expression pattern is enriched in prosurvival genes and pathways that promote PCa progression
To identify the prosurvival proteins and pathways that could be promising therapeutic targets against both IL-1-senstive AR + PCa cells that downregulate or lose AR and AR -PCa cells that have evolved IL-1independent constitutive pathways, we identified an IL-1-confered gene expression pattern in the AR + LNCaP PCa cell line that is intrinsic to the AR − PC3 PCa cell line (Figure 1 and Supplementary Table S1 ).
The gene expression pattern is enriched in inflammatory and immune response signaling pathways ( Figure 6A ) that mediate inflammationinduced tumorigenicity and provide cellular defense against the inflammatory microenvironment. For example, NFκB 38 and two of its many downstream inflammatory signaling molecules, IL-8 39, 40 and iNOS, 31, 41 have been shown to promote androgen receptor-independent PCa cell survival.
NFκB is an inflammatory, immune, and antioxidant response transcription factor that inhibits PCa cell apoptosis and promotes PCa cell metastasis and skeletal colonization. 30, 39 NFκB protein levels and activity are elevated in PCa patients and AR − PCa cell lines. 30 p62 and ELF3, two of the selected genes that we confirmed by RT-QPCR and/ or Western blot analysis to be induced by IL-1 in AR + PCa cell lines and basally high in AR − PCa cell lines (Figures 3, S1 , and S2), encode proteins that promote IL-1-induced NFκB signaling. In response to IL-1, p62 binds and adds activating ubiquitin to TRAF6, leading to downstream NFκB activation 18 and IL-1β induces expression of the ELF3 transcription factor through an ELF3-NFκB positive feedback loop. 42 Both p62 43 and ELF3 42 are elevated in PCa patient tissue; and constitutive ELF3 overexpression has been shown to enhance PCa xenograft tumor growth, 42 while p62 downregulation reduces cell viability in AR − PCa cell lines. 16 Thus, the IL-1-activated or constitutive p62-NFκB and/or ELF3-NFκB axes may promote AR-independent survival and tumorigenic behavior for AR low/− PCa cells.
In addition to p62 and ELF3, the other selected IL-1-induced genes, SOX9, CD44, and CD24 (Figures 3, S1 , and S2), also encode proteins that are important in PCa initiation and progression. SOX9 is a cell fate determinant transcription factor that regulates normal prostate cell development. [44] [45] [46] SOX9 is elevated in PCa tissue, correlates with tumor progression, represses AR activity in PCa cells, shows inverse accumulation with AR in prostate glands, and promotes PCa tumor growth in xenograft and genetic mouse models. [44] [45] [46] and CD44 are glycoproteins that are used to distinguish prostate cell subpopulations at different cell fate stages. CD44 is expressed in AR − neuroendocrine and stem cells 36, 47 and CD24 + cells represent transient amplifying cells. 48 CD24 is associated with poor prognosis 49 and CD44 + enriched stem cell populations promote PCa tumorigenicity and androgen-resistant tumor growth. 47, 50, 51 Thus, IL-1 may regulate cell fate programs that provide AR low/− PCa cells with a survival and tumor-promoting advantage.
The repressed genes in our gene expression profile are equally as important in PCa progression as the elevated genes. For example, the AR target gene, NKX3.1, encodes a PCa tumor suppressor protein that is reduced or lost in PCa patient tissue and cooperates with PTEN loss to promote PCa initiation. 52 Interestingly, our enrichment analysis suggests that PTEN signaling is downregulated in our gene expression profile ( Figure 6 ). Thus, IL-1-repressed NKX3.1 expression would be expected to facilitate the survival and promote tumorigenicity of AR low/− PCa cells.
| CONCLUSIONS
In closing, the IL-1-conferred gene expression profile that we identified in AR + LNCaP cells that mimics AR − PC3 gene expression patterns reveals potential prosurvival, tumorigenic pathways, and proteins that could be effective targets to prevent IL-1-induced AR low/ − PCa de novo accumulation and to eliminate existing AR − PCa cells, thereby, thwarting PCa hormone therapy resistance and AR-independent survival and tumor progression. Of note, as we have previously shown for IL-1 regulation of p62 versus AR, 4 our expression profile includes genes that are regulated both independently (eg, p62) and dependently (eg, AR target genes such as PSA) of IL-1-induced AR repression. It will be important to delineate the independent versus dependent genes, as genes that encode for signaling pathways conferring survival or tumor-promoting advantages independent of AR repression would be particularly advantageous in the face of ARtargeting therapies. For example, a cell exposed to AR-targeting therapy in an IL-1-rich microenvironment would, concomitant with losing target AR, still be able to elicit p62 pathways independent of AR repression and, thus, would be expected to still survive and promote tumor progression. As a next step, it will also be important to prioritize the genes in our expression profile and to characterize their IL-1mediated mechanistic regulation and their functional significance in PCa treatment resistance and AR-independent survival and tumor progression in order to identify novel therapeutic targets and identify PCa patients that would benefit from novel therapies.
